Page last updated: 2024-12-08

2,4,5-trihydroxypentanoic acid gamma-lactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID161815
CHEMBL ID98888
CHEBI ID17281
SCHEMBL ID3394583
MeSH IDM0158199

Synonyms (33)

Synonym
CHEMBL98888
34371-14-7
2-deoxy-d-erythro-pentonic acid gamma-lactone
2,4,5-trihydroxypentanoic acid gamma-lactone
CHEBI:17281 ,
(4s,5r)-4-hydroxy-5-(hydroxymethyl)dihydrofuran-2(3h)-one
2-deoxy-d-ribono-1,4-lactone
2-deoxy-ribono-1,4-lactone
2-deoxyribonolactone
C02674
deoxyribonolactone ,
SCHEMBL3394583
(4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-one
2'-deoxyribolactone
d-erythro-pentonic acid, 2-deoxy-, gamma-lactone
2-deoxy-d-ribonic-1,4-lactone
2-deoxy-d-ribonic acid-1,4-lactone
73209-20-8
AKOS022184490
W-202407
(4s,5r)-4-hydroxy-5-(hydroxymethyl)dihydro-2(3h)-furanone
mfcd15144952
2-deoxy-d-ribono-1,4-lactone, >=95% (gc)
P19126
YIXDEYPPAGPYDP-IUYQGCFVSA-N
2-deoxyribono-1,4-lactone
CS-0053170
DS-18636
Q27102301
AMY34444
rel-(4s,5r)-4-hydroxy-5-(hydroxymethyl)dihydrofuran-2(3h)-one
DTXSID501308989
EN300-1699866
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ribonolactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID616386Antioxidant activity assessed DPPH scavenging activity at 500 uM2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID616383Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
AID160560The percentage decrease in the binding of [3H]PGE2, in the presence of 1000 uM of compound2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Enantioselective synthesis and biological activity of (3S,4R)- and (3S,4S)-3-hydroxy-4-hydroxymethyl- 4-butanolides in relation to PGE2.
AID160686The percentage decrease in the binding of [3H]PGE2, in the presence of 125 uM of compound2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Enantioselective synthesis and biological activity of (3S,4R)- and (3S,4S)-3-hydroxy-4-hydroxymethyl- 4-butanolides in relation to PGE2.
AID616299Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation2011Journal of natural products, Sep-23, Volume: 74, Issue:9
Anti-inflammatory principles from Cordyceps sinensis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (8.20)18.7374
1990's6 (9.84)18.2507
2000's37 (60.66)29.6817
2010's12 (19.67)24.3611
2020's1 (1.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.97 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (6.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (93.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]